Wang Haocheng, Shan Dongfeng, Dong Ya, Yang Xue, Zhang Linwei, Yu Zhuang
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China.
Oncol Lett. 2021 Jan;21(1):73. doi: 10.3892/ol.2020.12334. Epub 2020 Nov 25.
Related studies have reported that cystatin C (Cys C), uric acid (UA) and lactate dehydrogenase (LDH) affect tumor growth and invasion; however, the correlation between them and the prognosis of patients with small-cell lung cancer (SCLC) remains unclear. The present study aimed to investigate the effects of serum Cys C, UA and LDH concentrations on the prognosis of patients with SCLC prior to initial treatment, in order to identify potential targets for determining the clinical outcome of patients with SCLC. A total of 205 patients with SCLC were enrolled in the present study, and the clinical and laboratory data were obtained from the medical records. The receiver operating characteristic curve was used to determine the optimal cut-off values of Cys C, UA and LDH, while the Kaplan-Meier method was used for survival analysis. The Cox proportional hazard model was used for univariate and multivariate analyses to identify independent prognostic factors. The optimal cut-off values for Cys C, UA and LDH were 0.775 mg/l, 296.45 µmol/l and 198.5 U/l, respectively. The survival curves demonstrated that progression-free survival (PFS) and overall survival (OS) time were shorter in patients with high levels of Cys C, UA and LDH prior to chemotherapy. Univariate and multivariate analyses indicated that LDH concentration prior to chemotherapy may be an independent prognostic factor for both PFS and OS in patients with SCLC, while Cys C concentration may be an independent prognostic factor for PFS in patients with SCLC. The concentrations of Cys C, UA and LDH prior to chemotherapy were associated with prognosis of patients with SCLC. PFS and OS time were shorter, and the prognosis was poor in patients with elevated serum levels of Cys C, UA and LDH. Taken together, the results of the present study suggest that high concentrations of LDH and Cys C prior to chemotherapy may indicate rapid disease progression, thus it is important to focus on the progression and recurrence of the disease. High LDH concentration may also indicate a shorter survival time.
相关研究报道,胱抑素C(Cys C)、尿酸(UA)和乳酸脱氢酶(LDH)会影响肿瘤的生长和侵袭;然而,它们与小细胞肺癌(SCLC)患者预后之间的相关性仍不明确。本研究旨在探讨初始治疗前血清Cys C、UA和LDH浓度对SCLC患者预后的影响,以确定预测SCLC患者临床结局的潜在指标。本研究共纳入205例SCLC患者,并从病历中获取临床和实验室数据。采用受试者工作特征曲线确定Cys C、UA和LDH的最佳截断值,同时采用Kaplan-Meier法进行生存分析。采用Cox比例风险模型进行单因素和多因素分析,以确定独立预后因素。Cys C、UA和LDH的最佳截断值分别为0.775mg/L、296.45μmol/L和198.5U/L。生存曲线显示,化疗前Cys C、UA和LDH水平较高的患者无进展生存期(PFS)和总生存期(OS)较短。单因素和多因素分析表明,化疗前LDH浓度可能是SCLC患者PFS和OS的独立预后因素,而Cys C浓度可能是SCLC患者PFS的独立预后因素。化疗前Cys C、UA和LDH浓度与SCLC患者的预后相关。血清Cys C、UA和LDH水平升高的患者PFS和OS时间较短,预后较差。综上所述,本研究结果表明,化疗前高浓度的LDH和Cys C可能提示疾病进展迅速,因此关注疾病的进展和复发很重要。高LDH浓度也可能提示较短的生存时间。